2,888 Shares in Incyte Co. (NASDAQ:INCY) Purchased by CoreCap Advisors LLC

CoreCap Advisors LLC bought a new position in shares of Incyte Co. (NASDAQ:INCY – Get Rating) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 2,888 shares of the biopharmaceutical company’s stock, valued at approximately $232,000.

Other hedge funds have also made changes to their positions in the company. General Partner Inc. acquired a new stake in shares of Incyte during the 4th quarter worth about $25,000. Guardian Wealth Advisors LLC bought a new stake in Incyte during the 3rd quarter worth about $29,000. CI Investments Inc. grew its holdings in Incyte by 76.7% during the 3rd quarter. CI Investments Inc. now owns 507 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 220 shares during the last quarter. Parkside Financial Bank & Trust grew its holdings in Incyte by 91.0% during the 1st quarter. Parkside Financial Bank & Trust now owns 447 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 213 shares during the last quarter. Finally, Itau Unibanco Holding S.A. bought a new stake in Incyte during the 3rd quarter worth about $51,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Incyte Stock Performance

Shares of INCY stock opened at $62.87 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.91 and a current ratio of 3.95. The company has a market capitalization of $14.03 billion, a P/E ratio of 43.36, a price-to-earnings-growth ratio of 3.18 and a beta of 0.72. The company’s 50 day moving average price is $70.49 and its two-hundred day moving average price is $76.51. Incyte Co. has a 52 week low of $62.48 and a 52 week high of $86.29.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. TheStreet lowered shares of Incyte from a “b-” rating to a “c” rating in a report on Tuesday, February 7th. Piper Sandler reissued an “overweight” rating and set a $100.00 price objective on shares of Incyte in a report on Wednesday, February 8th. VNET Group reaffirmed a “maintains” rating on shares of Incyte in a research note on Wednesday, May 3rd. Cowen raised their target price on shares of Incyte from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, February 8th. Finally, Morgan Stanley raised their target price on shares of Incyte from $76.00 to $77.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 12th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Incyte currently has a consensus rating of “Hold” and an average price target of $81.50.

About Incyte

(Get Rating)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company was founded in April 1991 and is headquartered in Wilmington, DE.